- A World Health Organization (WHO) panel has backed the use of Merck & Co Inc's (NYSE:MRK) COVID-19 antiviral pill for high-risk patients.
- The expert panel conditionally recommended molnupiravir for patients with non-severe disease at high risk of hospitalization, such as the immunocompromised, the unvaccinated, older people, and those with chronic conditions.
- The recommendation was based on new data from six clinical trials involving 4,796 patients.
- Related: See Why Did FDA Update Merck's COVID-19 Pill Emergency Use Authorization.
- Since molnupiravir's U.S. authorization in December, demand for the pill among COVID-19 patients has taken a hit from comparatively low efficacy.
- The panel also updated its guidance for the use of Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) casirivimab-imdevimab COVID-19 antibody cocktail.
- It now recommends the drug only for people who are not infected with omicron as new data has shown it is not effective against the variant.
- Price Action: MRK shares closed 0.70% higher at $77.21 on the last check Thursday.
- Photo by Thomas Breher from Pixabay
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
WHO Conditionally Recommends Merck's COVID-19 Antiviral Pill For High-Risk Patients
Merck
WHO
MRK
FDA
NYSE
Pixabay
Regeneron Pharmaceuticals Inc
United States
World Health Organization
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks